Freedom of Information request on Adverse drug reaction data for COVID-19 vaccines broken down by local authority or CCG (FOI 21/1149)
Published 26 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-8-november-2021/freedom-of-information-request-on-adverse-drug-reaction-data-for-covid-19-vaccines-broken-down-by-local-authority-or-ccg-foi-211149
FOI 21/1149
12th November 2021
Dear,
Thank you of your email dated 19th October 2021, where you requested:
Adverse drug reaction data for COVID-19 vaccines broken down by local authority or CCG
We can confirm that the MHRA does hold some of the information that you have requested. However, we have also determined that the information is exempt under Section 12 of the Freedom of Information Act and we cannot process your request any further. Section 12 of the Act allows public authorities to refuse requests where the cost of dealing with them would exceed the appropriate limit, which for central government is set at £600. This represents the estimated cost of one person spending 24 working hours in determining whether the department holds the information, locating, retrieving and extracting the information.
If your request can be restricted, for example to specific CCGs, then we will be happy to reconsider your FOI request and provide you with this information.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division